NFKB1 and lymphoma: Since several lymphoid cancers have been found to critically rely on constitutive NF-κB activity for their survival and since the anti-apoptotic effects of NF-κB activation can confer resistance towards cancer chemotherapy [246], inhibition of NF-κB activation represents an attractive therapeutic option in many lymphoid malignancies.